Furmonertinib in EGFR-Mutant NSCLC With Brain Metastases (iFORCE)

Sponsor
Peking Union Medical College
Study ID
NCT05465343
Phase
PHASE2
Status
Completed

Conditions

  • Brain Metastases
  • EGFR-mutation
  • Furmonertinib
  • NSCLC

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is a single-arm, open-label, prospective phase II trial. The aim of this phase II study is to evaluate the efficacy and safety of Furmonertinib in patients with EGFR mutation (including 19del or 21L858R or T790M) in advanced NSCLC with brain metastases.

Key Dates

Start date
Jul 11, 2022
Status verified
Dec 2025
Primary completion
Dec 12, 2025
Completion
Dec 12, 2025

Study Design

Enrollment
24 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: previously treated
    advanced NSCLC previously treated with systemic therapy, including chemotherapy and targeted therapy

Primary Outcome Measure

Intracranial Progression Free Survival (iPFS) [ Time Frame: Approximately 18 months after the first patient begin study treatment ]

Related Studies